Samsung Biologics and Episholdings Relisted on November 24

Bio Startup Venture Department, Reporter Donghoon Jung

Bio Startup Venture Department, Reporter Donghoon Jung

View original image

Samsung Biologics and Samsung Epish Holdings, which completed their spin-off, were both relisted on the KOSPI market on the 24th. This separation serves as a milestone that points the way forward for K-Bio, carrying significance that goes beyond mere stock price movements. It marks the first step in the restructuring of the Korean bio industry ecosystem.


Based on intensive investment in the bio sector, Samsung has built the world’s largest contract development and manufacturing organization (CDMO) business over the past decade, and has elevated its biosimilar development capabilities to a global level, driving the quantitative growth of Korea’s bio industry. Through this spin-off, Samsung Biologics has further refined its identity as a “pure-play CDMO,” while the newly launched Samsung Epish Holdings has acquired a new growth engine focused on new drug development and investment in the bio ecosystem. Thus, the split between the two companies is not a division, but rather an expansion and a strategic upgrade.


Looking back, Samsung has always played a pioneering role in Korea’s key industries such as semiconductors, home appliances, and petrochemicals. Large-scale facility investments, technological development, and swift decision-making have been the backbone supporting the competitiveness of Korean manufacturing. The construction of Samsung’s domestic and overseas plants and the establishment of its value chain have naturally driven the growth of domestic small and medium-sized enterprises (SMEs) specializing in materials, components, and equipment. Once the “big tree” of Samsung takes root, countless SMEs flourish beneath it, creating a rich ecosystem.


Samsung’s role as a “big pharma” in the bio sector is also crucial. Recently, the global landscape of new drug development has rapidly shifted to one where the success of major pharmaceutical companies, or big pharma, depends on how well they nurture innovative biotech ecosystems. Next-generation anticancer drugs such as antibody-drug conjugates (ADCs), central nervous system (CNS) therapies, and obesity treatments are each growing into markets worth hundreds of trillions of won.


Big pharma is no longer a company that handles all research and production in-house. Its identity is being redefined as a driving force that proactively discovers innovative biotech companies and enriches the entire ecosystem through bold acquisitions or collaborations. Pfizer acquired Seagen, a leader in ADC technology, for $43 billion (about 63 trillion won), while AbbVie spent $10.1 billion (about 14 trillion won) to acquire another ADC biotech, ImmunoGen. As such, global big pharma’s efforts to acquire promising biotech firms, invest capital, and expand their reach through technology deals are accelerating throughout the global bio industry.


Global big pharma companies are making these decisions because they understand better than anyone that innovation arises not only from their own research labs but from the entire ecosystem. Samsung Biologics, with its capital strength to pursue large-scale mergers and acquisitions (M&A) or technology transfer deals, and its personnel and systems capable of discerning the best among numerous biotech firms and pipelines, has quietly joined the ranks of big pharma.



If a major domestic player like Samsung Biologics begins to act as a direct “buyer of innovation,” the landscape of the Korean bio industry could change dramatically. It could also serve as a catalyst to revive the investment sentiment in the bio sector, which has been frozen for years. The market hopes that Samsung’s participation in the bio ecosystem will go beyond one company’s growth strategy and become an opportunity to transform the overall structure of the Korean bio industry.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing